Search research articles
Contact Us
Filters
Showing results (1381-1390 of 1,472) with videos related to
Page
of 148
Sort By:
Health Technology Assessment (Winchester, England)
|
February 3, 2026
The impact and cost-effectiveness of scaling up HCV treatment for achieving elimination among people who inject drugs in England: a synopsis including evidence synthesis and economic modelling
Zoe Ward, Ruth Simmons, Hannah Fraser, et al.
Journal of Gastroenterology and Hepatology
|
March 18, 2011
Insulin resistance is independently associated with significant hepatic fibrosis in Asian chronic hepatitis C genotype 2 or 3 patients
Keyur Patel, Alexander J Thompson, Wan-Long Chuang, et al.
The Lancet Regional Health. Europe
|
January 6, 2025
Impact and cost-effectiveness of scaling up HCV testing and treatment strategies for achieving HCV elimination among people who inject drugs in England: a mathematical modelling study
Zoe Ward, Ruth Simmons, Hannah Fraser, et al.
Toxicologic Pathology
|
April 23, 2016
Characterizing "Adversity" of Pathology Findings in Nonclinical Toxicity Studies: Results from the 4th ESTP International Expert Workshop
Xavier Palazzi, John E Burkhardt, Henri Caplain, et al.
Journal of Viral Hepatitis
|
December 17, 2009
Prevalence of chronic viral hepatitis in people of south Asian ethnicity living in England: the prevalence cannot necessarily be predicted from the prevalence in the country of origin
G Uddin, D Shoeb, S Solaiman, et al.
Journal of Hepatology
|
March 20, 2018
High SVR12 with 8-week and 12-week glecaprevir/pibrentasvir therapy: An integrated analysis of HCV genotype 1-6 patients without cirrhosis
Massimo Puoti, Graham R Foster, Stanley Wang, et al.
Cancer Chemotherapy and Pharmacology
|
August 31, 2002
A phase I study of the GM-CSF antagonist E21R
Ian N Olver, Tim Hercus, Angel Lopez, et al.
Journal of Viral Hepatitis
|
October 8, 2014
HCV treatment rates and sustained viral response among people who inject drugs in seven UK sites: real world results and modelling of treatment impact
N K Martin, G R Foster, J Vilar, et al.
Investigational New Drugs
|
June 19, 2015
Multicenter phase II study of the AKT inhibitor MK-2206 in recurrent or metastatic nasopharyngeal carcinoma from patients in the mayo phase II consortium and the cancer therapeutics research group (MC1079)
B B Y Ma, B C Goh, W T Lim, et al.
Gut
|
August 30, 2011
Viral clearance is associated with improved insulin resistance in genotype 1 chronic hepatitis C but not genotype 2/3
Alexander J Thompson, Keyur Patel, Wan-Long Chuang, et al.
Page
of 148
Search research articles
Search
Showing results (1381-1390 of 1,472) with videos related to
Sort By:
Page
of 148
Health Technology Assessment (Winchester, England)
|
February 3, 2026
The impact and cost-effectiveness of scaling up HCV treatment for achieving elimination among people who inject drugs in England: a synopsis including evidence synthesis and economic modelling
Zoe Ward, Ruth Simmons, Hannah Fraser, et al.
Journal of Gastroenterology and Hepatology
|
March 18, 2011
Insulin resistance is independently associated with significant hepatic fibrosis in Asian chronic hepatitis C genotype 2 or 3 patients
Keyur Patel, Alexander J Thompson, Wan-Long Chuang, et al.
The Lancet Regional Health. Europe
|
January 6, 2025
Impact and cost-effectiveness of scaling up HCV testing and treatment strategies for achieving HCV elimination among people who inject drugs in England: a mathematical modelling study
Zoe Ward, Ruth Simmons, Hannah Fraser, et al.
Toxicologic Pathology
|
April 23, 2016
Characterizing "Adversity" of Pathology Findings in Nonclinical Toxicity Studies: Results from the 4th ESTP International Expert Workshop
Xavier Palazzi, John E Burkhardt, Henri Caplain, et al.
Journal of Viral Hepatitis
|
December 17, 2009
Prevalence of chronic viral hepatitis in people of south Asian ethnicity living in England: the prevalence cannot necessarily be predicted from the prevalence in the country of origin
G Uddin, D Shoeb, S Solaiman, et al.
Journal of Hepatology
|
March 20, 2018
High SVR12 with 8-week and 12-week glecaprevir/pibrentasvir therapy: An integrated analysis of HCV genotype 1-6 patients without cirrhosis
Massimo Puoti, Graham R Foster, Stanley Wang, et al.
Cancer Chemotherapy and Pharmacology
|
August 31, 2002
A phase I study of the GM-CSF antagonist E21R
Ian N Olver, Tim Hercus, Angel Lopez, et al.
Journal of Viral Hepatitis
|
October 8, 2014
HCV treatment rates and sustained viral response among people who inject drugs in seven UK sites: real world results and modelling of treatment impact
N K Martin, G R Foster, J Vilar, et al.
Investigational New Drugs
|
June 19, 2015
Multicenter phase II study of the AKT inhibitor MK-2206 in recurrent or metastatic nasopharyngeal carcinoma from patients in the mayo phase II consortium and the cancer therapeutics research group (MC1079)
B B Y Ma, B C Goh, W T Lim, et al.
Gut
|
August 30, 2011
Viral clearance is associated with improved insulin resistance in genotype 1 chronic hepatitis C but not genotype 2/3
Alexander J Thompson, Keyur Patel, Wan-Long Chuang, et al.
Page
of 148